The state of Illinois currently has 4 active clinical trials seeking participants for Amyotrophic Lateral Sclerosis research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
Analysis of Human ALS Tissues and Registry of ALS Patients
Recruiting
Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig's Disease, is a progressive, terminal condition of muscle weakness that is associated with degeneration of neurons in the spinal cord and brain. This devastating disorder afflicts people in the prime of their lives. At the present time, there are no cures for this disorder, and current treatments are marginal at best. Despite years of intensive research, a fundamental understanding of this disease is still lacking. There is a n... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
06/18/2024
Locations: University of Illinois at Chicago, Chicago, Illinois
Conditions: Amyotrophic Lateral Sclerosis
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
Recruiting
The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen and to evaluate the effect of tofersen on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest amyotrophic lateral sclerosis (ALS).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)
Recruiting
ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) represents the formalized integration of ARTFL (U54 NS092089; funded through 2019) and LEFFTDS (U01 AG045390; funded through 2019) as a single North American research consortium to study FTLD for 2019 and beyond.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/12/2024
Locations: Northwestern University, Chicago, Illinois
Conditions: Frontotemporal Lobar Degeneration (FTLD), Progressive Supranuclear Palsy (PSP), Corticobasal Degeneration (CBD), Behavioral Variant Frontotemporal Dementia (bvFTD), Semantic Variant Primary Progressive Aphasia (svPPA), Nonfluent Variant Primary Progressive Aphasia (nfvPPA), FTD With Amyotrophic Lateral Sclerosis (FTD/ALS), Amyotrophic Lateral Sclerosis, Oligosymptomatic PSP (oPSP), C9orf72, GRN Related Frontotemporal Dementia, MAPT Gene Mutation, TBK1 Gene Mutation, Oligosymptomatic Progressive Supranuclear Palsy
Telehealth Implementation of Brain-Computer Interface
Recruiting
Determine if Telehealth intervention can allow/empower a caregiver (who is untrained) to effectively implement and utilize a Brain-Computer Interface for communication with a participant who is "Locked in" following progression of Amyotrophic Lateral Sclerosis and other conditions.
Gender:
All
Ages:
Between 16 years and 100 years
Trial Updated:
07/18/2023
Locations: ShirleyRyan AbilityLab, Chicago, Illinois
Conditions: Amyotrophic Lateral Sclerosis, Stroke